L20.9
Conditions
Interventions
Group 1: Non-interventional and non-comparative cohort study.
Patients who have completed the LP0162-1337 ECZTEND clinical trial in Germany and have agreed to continue treatment with commercially avai
Sponsors
LEO Pharma A/S
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: -Adult patients eligible for treatment with tralokinumab according to the national, approved label where the decision to prescribe tralokinumab has been made prior to and independently of enrolment in the study. -Signed and dated informed consent. -Participated in the ECZTEND clinical trial and decision to continue tralokinumab treatment with commercially available drug.
Exclusion criteria
Exclusion criteria: -Participation in the active treatment phase of a clinical trial. -Previous enrolment in the study. -Contraindications according to the label.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective is to evaluate the long-term effect of tralokinumab. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objectives are to explore treatment patterns and reasons for treatment changes; to characterize long-term responders; and to evaluate the long-term safety of tralokinumab. | — |
Countries
Germany
Contacts
Public ContactLaura Langer
IQVIA Commercial GmbH & Co. OHG
Outcome results
None listed